Literature DB >> 16284914

Sample size computations for PK/PD population models.

Dongwoo Kang1, Janice B Schwartz, Davide Verotta.   

Abstract

We describe an accurate, yet simple and fast sample size computation method for hypothesis testing in population PK/PD studies. We use a first order approximation to the nonlinear mixed effects model and chi-square distributed Wald statistic to compute the minimum sample size to achieve given degree of power in rejecting a null hypothesis in population PK/PD studies. The method is an extension of Rochon's sample size computation method for repeated measurement experiments. We compute sample sizes for PK and PK/PD models with different conditions, and use Monte Carlo simulation to show that the computed sample size retrieves the required power. We also show the effect of different sampling strategies, such as minimal, i.e., as many observations per individual as parameters in the model, and intensive on sample size. The proposed sample size computation method can produce estimates of minimum sample size to achieve the desired power in hypothesis testing in a greatly reduced time than currently available simulation-based methods. The method is rapid and efficient for sample size computation in population PK/PD study using nonlinear mixed effect models. The method is general and can accommodate any type of hierarchical models. Simulation results suggest that intensive sampling allows the reduction of the number of patients enrolled in a clinical study.

Entities:  

Mesh:

Year:  2005        PMID: 16284914     DOI: 10.1007/s10928-005-0078-3

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  19 in total

1.  On sample size calculation in bioequivalence trials.

Authors:  S C Chow; H Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

2.  Optimization of individual and population designs using Splus.

Authors:  Sylvie Retout; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

3.  Sample size requirement for repeated measurements in continuous data.

Authors:  K J Lui; W G Cumberland
Journal:  Stat Med       Date:  1992-03       Impact factor: 2.373

Review 4.  Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems.

Authors:  D Verotta
Journal:  Crit Rev Biomed Eng       Date:  1996

5.  Optimal experiment design for nonlinear models subject to large prior uncertainties.

Authors:  E Walter; L Pronzato
Journal:  Am J Physiol       Date:  1987-09

6.  Kinetics of interaction between drugs and biological systems.

Authors:  G Segre
Journal:  Farmaco Sci       Date:  1968-10

7.  Sample size requirements and the cost of a randomized clinical trial with repeated measurements.

Authors:  D A Bloch
Journal:  Stat Med       Date:  1986 Nov-Dec       Impact factor: 2.373

8.  Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses.

Authors:  D R Abernethy; J B Schwartz; E L Todd; R Luchi; E Snow
Journal:  Ann Intern Med       Date:  1986-09       Impact factor: 25.391

9.  Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking.

Authors:  Dongwoo Kang; Davide Verotta; Mary Ellen Krecic-Shepard; Nishit B Modi; Suneel K Gupta; Janice B Schwartz
Journal:  Clin Pharmacol Ther       Date:  2003-01       Impact factor: 6.875

10.  Hemodynamic regulation in SHR: investigation by spectral analysis.

Authors:  S Akselrod; S Eliash; O Oz; S Cohen
Journal:  Am J Physiol       Date:  1987-07
View more
  12 in total

1.  Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

Authors:  Camille Vong; Martin Bergstrand; Joakim Nyberg; Mats O Karlsson
Journal:  AAPS J       Date:  2012-02-17       Impact factor: 4.009

2.  How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Eur J Clin Pharmacol       Date:  2008-05-16       Impact factor: 2.953

3.  Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.

Authors:  Dirk Jan A R Moes; Rogier R Press; Jan den Hartigh; Tahar van der Straaten; Johan W de Fijter; Henk-Jan Guchelaar
Journal:  Clin Pharmacokinet       Date:  2012-07-01       Impact factor: 6.447

4.  Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug-drug interaction studies.

Authors:  Shuying Yang; Misba Beerahee
Journal:  Eur J Clin Pharmacol       Date:  2010-12-02       Impact factor: 2.953

5.  Predicting Antibiotic Effect of Vancomycin Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation: Dense Sampling versus Sparse Sampling.

Authors:  Yong Kyun Kim; Jae Ha Lee; Hang-Jea Jang; Dae Young Zang; Dong-Hwan Lee
Journal:  Antibiotics (Basel)       Date:  2022-05-31

6.  Estimation of cefepime, piperacillin, and tazobactam clearance with iohexol-based glomerular filtration rate in paediatric patients.

Authors:  Hiie Soeorg; Aveli Noortoots; Maarja Karu; Kadri Saks; Jana Lass; Irja Lutsar; Lenne-Triin Kõrgvee
Journal:  Eur J Clin Pharmacol       Date:  2022-03-11       Impact factor: 2.953

7.  Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.

Authors:  Eliford Ngaimisi Kitabi; Omary Mashiku Sylivester Minzi; Sabina Mugusi; Philip Sasi; Mohamed Janabi; Ferdinand Mugusi; Leif Bertilsson; Jürgen Burhenne; Eleni Aklillu
Journal:  Sci Rep       Date:  2018-11-05       Impact factor: 4.379

8.  Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.

Authors:  Constant Edi; Catherine M Bjerum; Allassane F Ouattara; Yashpal S Chhonker; Louis K Penali; Aboulaye Méité; Benjamin G Koudou; Gary J Weil; Christopher L King; Daryl J Murry
Journal:  PLoS Negl Trop Dis       Date:  2019-05-20

9.  Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy.

Authors:  Roger J W Hill; Pasquale F Innominato; Francis Lévi; Annabelle Ballesta
Journal:  PLoS Comput Biol       Date:  2020-01-27       Impact factor: 4.475

10.  Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.

Authors:  D J A R Moes; J J Swen; J den Hartigh; T van der Straaten; J J Homan van der Heide; J S Sanders; F J Bemelman; J W de Fijter; H J Guchelaar
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.